|
Expert Perspectives on Practice-Changing Strategies for Improved Patient Outcomes in Multiple Myeloma - Part 1
STATEMENT OF NEED
Multiple myeloma is a B-cell neoplasm that occurs primarily in older adults. The incidence is expected to rise in conjunction with the aging population. Because symptoms often do not appear until the malignancy is in advanced stages, early diagnosis is difficult, and the 5-year relative survival rate remains only 54% (ACS, 2021). Following diagnosis, management must be guided by cytogenic markers with prognostic significance and correct staging based upon these markers (NC... |
|
|
Expert Perspectives on Practice-Changing Strategies for Improved Patient Outcomes in Multiple Myeloma - Part 2
STATEMENT OF NEED
Multiple myeloma is a B-cell neoplasm characterized by expansion of plasma cells within the bone marrow and extramedullary sites (ACS, 2021). For patients who relapse, treatment becomes increasingly complex, and outcomes worsen with each relapse (Siegal et al, 2020). Advanced multiple myeloma may be associated with considerable disease-related comorbidities in addition to treatment-related adverse events and impaired quality of life, all of which increase the challenges of... |
|
|
Addressing Barriers to Improved Outcomes in African American Patients With Multiple Myeloma
Target Audience
This activity is designed to meet the educational needs of Oncology NPs, PAs, and nurses.
Program Overview
Multiple myeloma is the second most common blood cancer in the United States, and its incidence in the African American population is twice that of Whites. This activity offers learners the opportunity to engage in clinical scenarios of multiple myeloma in African American patients presented as 3 case vignettes, each featuring an expert-led video clip. Through the... |
|
|
Ocular Toxicities, Antibody-Drug Conjugates, and Multiple Myeloma: The Importance of Coordinating Ophthalmologic and Oncologic Care
The past two decades have seen the development of numerous new targeted therapies for multiple myeloma (MM). Included among these are antibody–drug conjugates (ADCs), which have shown significant promise in improving patient prognoses but are associated with unique adverse events (AEs). In particular, ADCs containing monomethyl auristatin F (MMAF) have been linked to increased incidence of corneal epithelial changes. With the FDA’s 2020 approval of belantamab mafodotin (the first ADC indic... |
|
|
Optimizing Treatment Sequencing for Patients With Relapsed/ Refractory Multiple Myeloma
Discover new developments in sequential treatment and clinical findings, evaluate strategies to manage and monitor adverse events, and initiating therapy for patients with relapsed/refractory Multiple Myeloma, and much more! Leading oncologist Shaji Kumar, Mayo Clinic Cancer Center, presents this in-depth discussion. Start the activity now!
STATEMENT OF NEED
Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramed... |
|
|
New Targets, New Combinations, New Treatment Goals: Assessing Therapeutic Options to Personalize Care in Multiple Myeloma
Target Audience
The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate.
Activity Overview
Almost all patients with multiple myeloma (MM) eventually relapse with the disease course typically involving multiple relapses and remissions. Therapy selection for relapsed or refractory (R/R) MM is nuanced and affected by many var... |
|
|
Expert Illustrations & Commentaries™: Roles and Rationales for BCMA-Directed Therapies in Multiple Myeloma
Target Audience
This educational program is directed toward medical oncologists/hematologists, and other oncology HCPs involved in the treatment of multiple myeloma. Advanced practitioners, nurses, pharmacists, and other healthcare professionals interested in multiple myeloma will be invited to participate.
Program Overview
This Expert Illustrations and CommentariesTM online activity is a video-based program in which 2 experts discuss emerging treatments in multiple myeloma (MM), name... |
|
|
Practical Tools & Expert Guidance for the Nurse Navigator and Clinical Team: Strategies to Reduce Treatment Disparities in Multiple Myeloma
This immersive practice guide offers a “how to” method for introducing day-to-day strategies in the real world through data, guidelines, and decision-making recommendations. Expert faculty address which approaches may not be working, complexities in managing this patient population, insights on how the latest evidence supports a practical recommendation and review available therapies to optimize treatment selection.
The prevalence of MM is higher in some racial/ethnic minorities and the... |
|
|
Optimizing Outcomes in Newly Diagnosed Multiple Myeloma: Integrating Anti-CD38 Monoclonal Antibody Therapy Into Clinical Practice
Target Audience
This activity is designed to meet the educational needs of the multiple myeloma care team including hematologists, oncologists, oncology advanced practice providers (APPs), oncology nurses, and allied health professionals (AHPs), such as pharmacists, medical technologists, and diagnostic medical sonographers.
Program Overview
Although multiple myeloma (MM) remains incurable, recent advances in therapy have led to improved outcomes. Given the recently approved and emerging ... |
|
|
A Glimpse Into Future of Myeloma Patient Management
ACTIVITY DESCRIPTION
In the last 18 years, oncology clinicians and patients have witnessed significant advances in multiple myeloma (MM) management, with the development of new strategies for establishing diagnosis, assessing prognosis, monitoring minimal residual disease (MRD), and delivering supportive care. In this time, 16 new drugs have been approved by the US Food and Drug Administration (FDA) for use in MM—including 10 in the last 6 years alone. The rapidity with which clinical data ... |
|
|
Community Practice Connections ®: New Targets, New Combinations, New Treatment Goals: Assessing Therapeutic Options to Personalize Care in Multiple Myeloma
Target Audience
The target audience for this activity is hematologists and oncologists who treat patients with MM. Physicians, nurses, and other health care professionals interested in the treatment of MM are also invited to participate.
Program Overview
Nearly all patients with multiple myeloma (MM) eventually relapse with the disease course typically involving multiple relapses and remissions. Therapy selection for relapsed or refractory (R/R) MM is nuanced and affected by many variable... |
|
|
Ace the Case: 79-Year-Old Man With Lower Back Pain, Increasing Fatigue, and Right Rib Pain
This activity utilizes a case study to discuss treatment options for transplant-ineligible multiple myeloma (MM) patients. |
|
|
Novel Therapeutic Strategies in Myeloma – Module 4
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides an overview of recent therapeutic advances for patients with newly diagnosed or relapsed multiple myeloma and the mechanisms by which novel therapies work.
Learning Objective
Upon completion of this activity, participants should be b... |
|
|
COVID-19, Vaccinations, and Blood Cancer Patients: The LLS Registry and Q&A – Module 5
Target Audience
This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.
Program Overview
This activity provides a review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination in patients with blood cancer and audience Q&A.
Learning Objective
Upon completion of this activity, participants should be better able ... |
|
|
Ace the Case: 71-Year-Old Woman With IgG Lambda Multiple Myeloma at Third Relapse
This activity utilizes a case study to discuss treatment options for multiple myeloma (MM) patients who have relapsed from previous therapies. |
|
|
Ace the Case: Worsening Fatigue and Diarrhea in a 64-Year-Old Woman With IgA Lambda Multiple Myeloma
This activity utilizes a case study to discuss early detection and intervention of treatment-related adverse events in patients with multiple myeloma (MM). |
|
|
Myeloma Masters: The Ultimate Myeloma Patient Care Quiz Show
Multiple myeloma management has advanced significantly in recent years, providing new hope for myeloma patients but creating new challenges for health care providers. Using an engaging and entertaining game show format (think Who Wants to Be a Millionaire), this activity tests players’ knowledge of current and emerging myeloma patient care best practices. Along the way—using a range of multimedia prompts and hints—the game presents information on several fast-evolving areas of myeloma ca... |
|
|
Myeloma Masters: The Ultimate Myeloma Patient Care Quiz Show
Target Audience
This activity has been designed to meet the educational needs of oncology nurses, advanced oncology certified nurse practitioners, and other health care providers involved in the care of patients with multiple myeloma.
Program Overview
Multiple myeloma management has advanced significantly in recent years, providing new hope for myeloma patients but creating new challenges for health care providers. Using an engaging and entertaining game show format (think Who Wants t... |
|
|
AL Amyloidosis: A Rare Blood Disorder with Multi-Organ Complications
Target Audience
The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, medical oncologists, hematologic oncologists, pathologists, radiologic oncologists, surgical oncologists, primary care providers, internists, oncology nurses, nurse navigators, nurse practitioners, physician assistants, and pharmacists.
Statement of Need/Program Overview
The wide range of symptoms for amyloidosis that overlap with other conditions often... |
|
|
Nursing Management of Bone Health in Patients with Cancer
Once it has metastasized to the skeletal system, cancer often negatively affects bone health, leading to pain, fractures, hypercalcemia, and nerve compression. This online activity reviews interventions to reduce morbodity and mortality of bone complications in patients with cancer.
STATEMENT OF NEED
Advanced-stage cancers, including lung, breast, prostate, and multiple myeloma, can have a detrimental effect on bone health (Coleman, Croucher et al, 2020). Once cancer spreads to the skel... |
|